RAD51 recruitment but not replication fork stability associates with PARP inhibitor response in ovarian cancer patient-derived xenograft models

Francien Talens, Vivian Oliviera Nunes Teixeira, Yannick P Kok, Mengting Chen, Efraim H Rosenberg, Rashmie Debipersad, Evelien W Duiker, Nathalie van den Tempel, Marketa Janatova, Petra Zemankova, Petra M Nederlof, G Bea A Wisman, Zdenek Kleibl, Steven de Jong, Marcel A T M van Vugt · 2024

Read RAD51 recruitment but not replication fork stability associates with PARP inhibitor response in ovarian cancer patient-derived xenograft models by Francien Talens, Vivian Oliviera Nunes Teixeira, Yannick P Kok, Mengting Chen, Efraim H Rosenberg, Rashmie Debipersad, Evelien W Duiker, Nathalie van den Tempel, Marketa Janatova, Petra Zemankova, Petra M Nederlof, G Bea A Wisman, Zdenek Kleibl, Steven de Jong, Marcel A T M van Vugt (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11604054.txt.

Description

Francien Talens and a large team of co-authors present a 2024 study on what predicts response to PARP inhibitor drugs in ovarian cancer. These drugs are standard for tumors with BRCA mutations, which cripple DNA repair. The team worked with thirty-one patient-derived tumor grafts grown in mice. About a quarter carried BRCA alterations, and half showed genomic instability. Fifteen grafts were treated with the drug olaparib to measure real response.

A lab test of repair function, counting RAD51 protein foci after radiation, identified every drug-sensitive graft, including four without BRCA changes. By contrast, measures of replication fork protection and speed did not track response at all. Sequencing of sensitive grafts lacking BRCA changes pointed to a variant in another gene as a possible cause. The authors conclude the RAD51 test can guide who should get these drugs, beyond mutation status alone.

Catalog record

CREATORFrancien Talens, Vivian Oliviera Nunes Teixeira, Yannick P Kok, Mengting Chen, Efraim H Rosenberg, Rashmie Debipersad, Evelien W Duiker, Nathalie van den Tempel, Marketa Janatova, Petra Zemankova, Petra M Nederlof, G Bea A Wisman, Zdenek Kleibl, Steven de Jong, Marcel A T M van Vugt
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE64 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11604054

Browse the full library · About the Tower of Babel